俄亥俄州和罗德岛州养老院居民接种二价COVID-19疫苗后对祖先SARS-CoV-2株及Omicron BA.1和BA.4/BA.5变异株的抗体反应,2022年9月至11月
对233名长期养老院居民从初种系列起连续采血检测抗刺突蛋白结合抗体和中和抗体滴度,包括后续加强针(含二价疫苗)。二价COVID-19 mRNA疫苗大幅提高针对Omicron亚系(包括BA.1和BA.4/BA.5)的抗刺突和中和抗体滴度,不论既往是否感染SARS-CoV-2或既往接种1或2剂加强针。结合养老院居民和工作人员二价加强针接种率低的证据,支持建议养老院居民和工作人员接种二价COVID-19加强针以降低相关发病和死亡。
要点
- 二价COVID-19 mRNA疫苗大幅提高养老院居民针对Omicron BA.1和BA.4/BA.5的抗刺突和中和抗体滴度。
- 抗体提升不论既往是否感染SARS-CoV-2或既往接种1或2剂加强针。
- 养老院居民和工作人员二价加强针接种率低,支持建议其接种二价加强针。
核心结论
- 二价COVID-19 mRNA疫苗大幅提高养老院居民针对Omicron亚系(包括BA.1和BA.4/BA.5)的抗刺突和中和抗体滴度,不论既往是否感染SARS-CoV-2或既往接种1或2剂加强针。
- 结合养老院居民和工作人员二价加强针接种率低的证据,支持建议养老院居民和工作人员接种二价COVID-19加强针以降低相关发病和死亡。
研究设计与样本
- 对233名长期养老院居民从初种系列起连续采血,检测抗刺突蛋白结合抗体和中和抗体滴度,包括后续加强针(含二价疫苗)。
主要发现
- 二价COVID-19 mRNA疫苗大幅提高针对Omicron亚系(包括BA.1和BA.4/BA.5)的抗刺突和中和抗体滴度。
- 抗体提升不论既往是否感染SARS-CoV-2或既往接种1或2剂加强针。
临床怎么用
- 支持建议养老院居民和工作人员接种二价COVID-19加强针以降低相关发病和死亡。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Introduction of monovalent COVID-19 mRNA vaccines in late 2020 helped to mitigate disproportionate COVID-19-related morbidity and mortality in U.S. nursing homes (1); however, reduced effectiveness of monovalent vaccines during the period of Omicron variant predominance led to recommendations for booster doses with bivalent COVID-19 mRNA vaccines that include an Omicron BA.4/BA.5 spike protein component to broaden immune response and improve vaccine effectiveness against circulating Omicron variants (2). Recent studies suggest that bivalent booster doses provide substantial additional protection against SARS-CoV-2 infection and severe COVID-19-associated disease among immunocompetent adults who previously received only monovalent vaccines (3).* The immunologic response after receipt of bivalent boosters among nursing home residents, who often mount poor immunologic responses to vaccines, remains unknown. Serial testing of anti-spike protein antibody binding and neutralizing antibody titers in serum collected from 233 long-stay nursing home residents from the time of their primary vaccination series and including any subsequent booster doses, including the bivalent vaccine, was performed. The bivalent COVID-19 mRNA vaccine substantially increased anti-spike and neutralizing antibody titers against Omicron sublineages, including BA.1 and BA.4/BA.5, irrespective of previous SARS-CoV-2 infection or previous receipt of 1 or 2 booster doses. These data, in combination with evidence of low uptake of bivalent booster vaccination among residents and staff members in nursing homes (4), support the recommendation that nursing home residents and staff members receive a bivalent COVID-19 booster dose to reduce associated morbidity and mortality (2).
引用
- Canaday DH, Oyebanji OA, White EM, et al. SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine - Ohio and Rhode Island, September-November 2022. MMWR Morb Mortal Wkly Rep. 2023. PMID: 36701254. doi:10.15585/mmwr.mm7204a4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。